GFM
GF Fund Management Portfolio holdings
AUM
$4.97B
This Quarter Return
+7.58%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$4.62B
AUM Growth
–
Cap. Flow
+$4.62B
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
48.03%
Holding
637
New
637
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
NVIDIA
NVDA
|
$390M |
| 2 |
Apple
AAPL
|
$374M |
| 3 |
Microsoft
MSFT
|
$322M |
| 4 |
Amazon
AMZN
|
$234M |
| 5 |
Meta Platforms (Facebook)
META
|
$194M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Technology | 45.53% |
| 2 | Consumer Discretionary | 17.29% |
| 3 | Communication Services | 14.35% |
| 4 | Healthcare | 6.6% |
| 5 | Consumer Staples | 4.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
626
Solid Biosciences
SLDB
$428M
| $3.36K | ﹤0.01% |
+839
| New | +$3.36K |
|
627
Sutro Biopharma
STRO
$89.9M
| $3.19K | ﹤0.01% |
+1,731
| New | +$3.19K |
|
|
TSVT
628
DELISTED
2seventy bio
TSVT
| $3.18K | ﹤0.01% |
+1,083
| New | +$3.18K |
|
629
TScan Therapeutics
TCRX
$108M
| $3.13K | ﹤0.01% |
+1,031
| New | +$3.13K |
|
630
Biomea Fusion
BMEA
$114M
| $3.04K | ﹤0.01% |
+784
| New | +$3.04K |
|
631
PepGen
PEPG
$45.9M
| $2.59K | ﹤0.01% |
+684
| New | +$2.59K |
|
632
Enanta Pharmaceuticals
ENTA
$189M
| $2.56K | ﹤0.01% |
+445
| New | +$2.56K |
|
|
CLYM
633
Climb Bio, Inc. Common Stock
CLYM
$162M
| $2.54K | ﹤0.01% |
+1,412
| New | +$2.54K |
|
634
Editas Medicine
EDIT
$248M
| $2.32K | ﹤0.01% |
+1,830
| New | +$2.32K |
|
|
OKUR
635
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$37.2M
| $2.29K | ﹤0.01% |
+266
| New | +$2.29K |
|
636
Pyxis Oncology
PYXS
$118M
| $1.95K | ﹤0.01% |
+1,249
| New | +$1.95K |
|
637
Q32 Bio
QTTB
$20.4M
| $881 | ﹤0.01% |
+256
| New | +$881 |
|